Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use - PubMed (original) (raw)
Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use
R L Burke. Rev Infect Dis. 1991 Nov-Dec.
Abstract
A herpes simplex virus subunit vaccine has been tested for immunogenicity and protective efficacy in animal models. The vaccine is a mixture of the viral glycoproteins gB and gD expressed in mammalian cells as secreted carboxyl terminal truncated derivatives. The antigens have been combined with several adjuvants, including a lipophilic derivative of a muramyl tripeptide, MTP-PE, and administered in a stable, low-oil emulsion. Titers of antibody that are threefold to 15-fold greater than those obtained with alum and within twofold of those generated with complete Freund's adjuvant are elicited in animals, including primates. Prophylactic immunization of guinea pigs provides nearly complete protection against intravaginal challenge with herpes simplex virus type 2. Treatment of previously infected guinea pigs reduces the frequency and severity of recurrent disease, although variations in efficacy dependent on the antigen, adjuvant, and dosing regimen employed are observed. The immunogenicity of this vaccine in animals provides the rationale for further testing in human clinical trials.
Similar articles
- The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
Sanchez-Pescador L, Burke RL, Ott G, Van Nest G. Sanchez-Pescador L, et al. J Immunol. 1988 Sep 1;141(5):1720-7. J Immunol. 1988. PMID: 2842401 - The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine.
Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G. Burke RL, et al. J Infect Dis. 1994 Nov;170(5):1110-9. doi: 10.1093/infdis/170.5.1110. J Infect Dis. 1994. PMID: 7963702 - Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT, Marshall JD, Dorwart MR, Heeke DS, Rao E, Tummala P, Yu L, Cohen GH, Eisenberg RJ, Sloan DD. Hensel MT, et al. J Virol. 2017 Apr 13;91(9):e02257-16. doi: 10.1128/JVI.02257-16. Print 2017 May 1. J Virol. 2017. PMID: 28228587 Free PMC article. - Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
Aurelian L, Smith CC, Wachsman M, Paoletti E. Aurelian L, et al. Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S924-34. doi: 10.1093/clind/13.supplement_11.s924. Rev Infect Dis. 1991. PMID: 1664130 Review. - Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model.
Stanberry LR. Stanberry LR. Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S920-3. doi: 10.1093/clind/13.supplement_11.s920. Rev Infect Dis. 1991. PMID: 1664129 Review.
Cited by
- Exacerbation of corneal scarring in HSV-1 gK-immunized mice correlates with elevation of CD8+CD25+ T cells in corneas of ocularly infected mice.
Allen SJ, Mott KR, Ljubimov AV, Ghiasi H. Allen SJ, et al. Virology. 2010 Mar 30;399(1):11-22. doi: 10.1016/j.virol.2009.12.011. Epub 2010 Jan 18. Virology. 2010. PMID: 20079918 Free PMC article. - Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease.
McClements WL, Armstrong ME, Keys RD, Liu MA. McClements WL, et al. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11414-20. doi: 10.1073/pnas.93.21.11414. Proc Natl Acad Sci U S A. 1996. PMID: 8876149 Free PMC article. - Current recommendations for the treatment of genital herpes.
Leung DT, Sacks SL. Leung DT, et al. Drugs. 2000 Dec;60(6):1329-52. doi: 10.2165/00003495-200060060-00007. Drugs. 2000. PMID: 11152015 Review. - Structure-function analysis of herpes simplex virus type 1 gD and gH-gL: clues from gDgH chimeras.
Cairns TM, Milne RS, Ponce-de-Leon M, Tobin DK, Cohen GH, Eisenberg RJ. Cairns TM, et al. J Virol. 2003 Jun;77(12):6731-42. doi: 10.1128/jvi.77.12.6731-6742.2003. J Virol. 2003. PMID: 12767993 Free PMC article. - Locations of herpes simplex virus type 2 glycoprotein B epitopes recognized by human serum immunoglobulin G antibodies.
Goade DE, Bell R, Yamada T, Mertz GJ, Jenison S. Goade DE, et al. J Virol. 1996 May;70(5):2950-6. doi: 10.1128/JVI.70.5.2950-2956.1996. J Virol. 1996. PMID: 8627770 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical